Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer.

ISRN Oncol · 2013 · PMC3676960 · PMID 23762609

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The response to lapatinib was numerically lower than to trastuzumab, although the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.